文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

四因子凝血酶原复合物逆转Xa因子抑制剂相关创伤性颅内出血

Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
PubMed 文献 · Am J Emerg Med · 2019-01-09
一句话结论回顾性队列显示,创伤性颅内出血患者使用4F-PCC与未逆转组相比,校正损伤严重度后死亡率和血栓栓塞并发症无显著差异。

该回顾性队列研究纳入2015年3月1日至2017年8月31日两家创伤中心服用Xa因子抑制剂并发生创伤性颅内出血的62例患者,比较接受4F-PCC(4F-PCC组)与未逆转(no reversal组)的结局。4F-PCC组损伤严重度评分显著更高(17.6 vs 12.1,p=0.019),院内死亡率更高(22.9% vs 3.7%,p=0.034),ICU住院时间更长(2.5 vs 1.4天,p=0.0024);未逆转组缺血性卒中/短暂性脑缺血发作发生率更高(0% vs 14.8%,p=0.019)。校正损伤严重度评分后,死亡率(p=0.20)、ICU住院时间(p=0.64)和缺血性卒中/短暂性脑缺血发作(p=0.94)均无显著差异。结论提示4F-PCC优先用于损伤更重患者,校正基线差异后死亡率和血栓栓塞并发症无差异。

要点

  • 4F-PCC组损伤严重度评分显著高于未逆转组(17.6 vs 12.1,p=0.019),提示4F-PCC优先用于损伤更重患者。
  • 未校正时4F-PCC组院内死亡率更高(22.9% vs 3.7%,p=0.034),ICU住院时间更长(2.5 vs 1.4天,p=0.0024)。
  • 未逆转组缺血性卒中/短暂性脑缺血发作发生率更高(0% vs 14.8%,p=0.019)。
  • 校正损伤严重度评分后,死亡率(p=0.20)、ICU住院时间(p=0.64)和缺血性卒中/短暂性脑缺血发作(p=0.94)均无显著差异。
  • 两组医院住院时间、出院去向、最终Activity Measure for Post Acute Care日常活动评分、静脉血栓栓塞和心肌梗死均无差异。

适用人群与场景

  • 服用Xa因子抑制剂并发生创伤性颅内出血的患者,来自2015年3月1日至2017年8月31日两家创伤中心。

研究设计与关键结果

  • 回顾性队列研究,纳入62例服用Xa因子抑制剂并发生创伤性颅内出血的患者,比较接受4F-PCC(4F-PCC组)与未逆转(no reversal组)的结局。
  • 4F-PCC组损伤严重度评分显著高于未逆转组(17.6 vs 12.1,p=0.019)。
  • 4F-PCC组院内死亡率显著高于未逆转组(22.9% vs 3.7%,p=0.034),ICU住院时间更长(2.5 vs 1.4天,p=0.0024)。
  • 未逆转组缺血性卒中/短暂性脑缺血发作发生率显著高于4F-PCC组(0% vs 14.8%,p=0.019)。
  • 校正损伤严重度评分后,死亡率(p=0.20)、ICU住院时间(p=0.64)和缺血性卒中/短暂性脑缺血发作(p=0.94)均无显著差异。
  • 两组医院住院时间、出院去向、最终Activity Measure for Post Acute Care日常活动评分、静脉血栓栓塞和心肌梗死均无差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 本研究表明,损伤严重度评分更高的患者优先接受4F-PCC,校正基线差异后4F-PCC与未逆转在死亡率、功能恢复、医院和ICU住院时间及血栓栓塞并发症方面无差异。

指南或共识出处

  • Am J Emerg Med

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The objective of this study was to determine the effectiveness and safety of four-factor prothrombin complex concentrate (4F-PCC) for the reversal of factor Xa inhibitors in patients with traumatic intracranial hemorrhage (ICH).

METHODS: This was a retrospective cohort study of patients taking factor Xa inhibitors with traumatic ICH between March 1, 2015 and August 31, 2017 at two trauma centers. The primary outcome was in-hospital mortality in patients who received 4F-PCC (4F-PCC group) compared to those who did not (no reversal group). Secondary outcomes included functional recovery, hospital and intensive care unit (ICU) length of stay (LOS), and thromboembolic complications.

RESULTS: There were 62 patients included in the study. Injury Severity Score (ISS) was significantly higher in the 4F-PCC group (17.6 vs. 12.1, p = 0.019). The 4F-PCC group had a significantly higher mortality (22.9% vs. 3.7%, p = 0.034) and longer ICU LOS (2.5 vs. 1.4 days, p = 0.0024). The no reversal group had a significantly higher incidence of ischemic stroke/transient ischemic attack (TIA) (0% vs. 14.8%, p = 0.019). After controlling for ISS, there was no significant difference in mortality (p = 0.20), ICU LOS (p = 0.64), or ischemic stroke/TIA (p = 0.94). There was no difference in hospital LOS, discharge disposition, final Activity Measure for Post Acute Care daily activity score, VTE, or MI.

CONCLUSION: Patients with a higher ISS received 4F-PCC preferentially, which led to an apparent mortality benefit the no reversal group. After adjusting for baseline differences between groups, there was no difference in mortality, functional recovery, hospital and ICU LOS, or thromboembolic complications.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Dybdahl D, Walliser G, Chance Spalding M, et al. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage. Am J Emerg Med. 2019. PMID: 30651183. doi:10.1016/j.ajem.2019.01.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。